Zydus Lifesciences is currently trading at Rate RS 929.45, up by 2.95 points or 0.32% from its previous close of Rate RS 926.50 on the BSE.

The stock opened at Rate RS 934.05 and has touched an intraday high of Rate RS 941.80 and a low of Rate RS 927.00. A total of 35,820 shares have been traded so far.

Classified under BSE group 'A', the stock with a face value of Rate RS 1 has recorded a 52-week high of Rate RS 1,323.90 on August 9, 2024, and a 52-week low of Rate RS 797.05 on April 7, 2025. Over the last week, the stock has moved between Rate RS 941.80 and Rate RS 916.85. The current market capitalization stands at Rate RS 94,163.38 crore.

Promoter holding in the company stands strong at 74.99%, while institutional and non-institutional investors hold 18.33% and 6.68%, respectively.

Zydus Lifesciences’ wholly owned subsidiary, Zynext Ventures USA LLC, has entered into a Securities Purchase Agreement (SPA) with U.S.-based Agenus Inc. to acquire 2,133,333 shares of common stock at a par value of $0.01 per share. The investment represents a 5.9% stake in Agenus on a fully diluted basis, at a purchase price of $7.50 per share, amounting to approximately $16 million.

Agenus’ flagship immunotherapy platform, which includes Botensilimab (BOT) and Balstilimab (BAL), is showing strong promise in advanced clinical trials. The therapies have demonstrated substantial clinical activity across nine cancer types in over 1,200 patients, spanning late-stage and neoadjuvant treatment settings.

This strategic investment aligns with Zydus Lifesciences’ mission to deliver transformative therapies grounded in science and innovation. Beyond capital, Zynext Ventures will contribute advanced data analytics capabilities and access to a wide network of biotech, regulatory, and clinical partners.

The collaboration is expected to help Agenus expand its BOT/BAL program into earlier lines of treatment and target a broader range of cancers with unmet medical needs. The acquisition is anticipated to be completed within 60 days of the definitive agreement, with the possibility of a 30-day extension.

Zydus Lifesciences (formerly Cadila Healthcare) is an integrated pharmaceutical company engaged in the full spectrum of research, development, production, marketing, and distribution of pharmaceutical products.